What is Zepbound?

What Zepbound is

Zepbound is Eli Lilly's brand of tirzepatide injection for chronic weight management and for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Tirzepatide activates receptors for two incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It is given once weekly under the skin.

This page explains the FDA-approved product. It is not medical advice, not a way to order Zepbound, and not a claim that Beema Health dispenses it. Beema does not sell branded Zepbound. A prescription is required. Licensed clinicians decide case by case. No weight-loss outcome is guaranteed.

FDA-approved indications

Used with a reduced-calorie diet and increased physical activity, Zepbound is indicated to reduce excess body weight and maintain that reduction long term in adults with obesity, or in adults with overweight who also have at least one weight-related comorbid condition (examples on labels and in trials include hypertension, dyslipidemia, OSA, or cardiovascular disease). It is separately indicated to treat moderate to severe OSA in adults with obesity.

Limitations of use on the prescribing information should be read in full. Zepbound is not studied as a substitute for a sleep-apnea device in every patient; SURMOUNT-OSA included people who were and were not using positive airway pressure. Diabetes care is the labeled role of Mounjaro, not Zepbound, even though both contain tirzepatide.

How Zepbound is taken

Zepbound is injected subcutaneously once weekly, any time of day, with or without meals, in the abdomen, thigh, or upper arm. Presentations include single-dose pens, single-dose vials, and in some strengths multi-dose vials or a KwikPen. Never share a pen. Storage and travel rules (refrigeration, time at room temperature) are on the Instructions for Use; see the travel-with-Zepbound article for a practical overview.

The recommended starting dosage for all indications is 2.5 mg weekly for four weeks. After four weeks, the dose increases to 5 mg weekly. Further increases of 2.5 mg may occur after at least four weeks on the current dose (5 to 7.5 to 10 to 12.5 to 15 mg). Maintenance for weight reduction is 5, 10, or 15 mg weekly. Maintenance for OSA is 10 or 15 mg weekly. Maximum dose is 15 mg weekly. The 2.5 mg strength is not an approved maintenance dose.

If gastrointestinal effects are hard to tolerate, clinicians may slow titration. Patients should not cut doses by 'counting clicks' on a pen or splitting vials unless a pharmacist and prescriber have given a specific, lawful instruction for that product presentation.

Who was studied in SURMOUNT trials

SURMOUNT-1 randomized adults with BMI of 30 or higher, or 27 or higher with a weight-related complication, without type 2 diabetes, to tirzepatide 5, 10, or 15 mg or placebo for 72 weeks. Mean weight reduction was dose-related and larger than placebo. Gastrointestinal events were the most common adverse reactions, especially during escalation.

SURMOUNT-4 asked what happens after weight has already been lost on tirzepatide. After a 36-week open-label lead-in, participants were randomized to continue tirzepatide or switch to placebo for 52 more weeks. People who continued generally maintained or added to their reduction; people switched to placebo regained a substantial fraction of the lost weight. That pattern informs maintenance conversations. It is physiology and trial evidence, not a scare tactic.

SURMOUNT-OSA evaluated tirzepatide 10 or 15 mg (maximum tolerated dose) versus placebo for 52 weeks in adults with obesity and moderate to severe OSA, with and without PAP therapy, and showed improvements in apnea-hypopnea index versus placebo. SURMOUNT-5 compared tirzepatide with semaglutide 2.4 mg in adults with obesity without diabetes and is discussed on the switching articles as brand-versus-brand trial data, not as a ranking of which medicine a given person 'should' take.

Labeled risks and when to get help

Zepbound's boxed warning addresses thyroid C-cell tumors in rodents. Human relevance is unknown. Do not use Zepbound with a personal or family history of medullary thyroid carcinoma or with MEN 2. Also avoid it after a known serious hypersensitivity to tirzepatide or excipients.

Severe gastrointestinal adverse reactions can occur. Zepbound is not recommended in severe gastroparesis. Vomiting and diarrhea can lead to dehydration and acute kidney injury. Acute gallbladder disease and acute pancreatitis are labeled concerns; discontinue if pancreatitis is suspected. Hypoglycemia can occur when combined with insulin or sulfonylureas. Hypersensitivity, including anaphylaxis and angioedema, has been reported. Tell anesthesia teams before procedures because of aspiration reports with this class.

Zepbound may cause fetal harm. Discuss contraception, pregnancy planning, and breastfeeding with a clinician. This is not a complete list of adverse reactions. Read the Medication Guide that ships with the pen.

Prescription-only status

Zepbound requires a prescription from a licensed U.S. clinician after an appropriate evaluation. Pages that invite people to 'buy Zepbound online' without that step are not describing lawful care.

Beema Health does not offer branded Zepbound. If you are looking for telehealth medical weight-loss information, Beema's program overview explains how an online visit works. If you already take Zepbound, do not stop or switch products without involving the clinician who knows your history. Related articles cover Zepbound dosing, switching to Wegovy, and stopping tirzepatide.

Frequently asked questions

Sources

1. [1] Zepbound (tirzepatide) U.S. Prescribing Information, Eli Lilly
2. [2] Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022.
3. [3] Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024.
4. [4] Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024.